联化科技股份有限公司 2020 年第三季度报告全文 联化科技股份有限公司 2020 年第三季度报告 二〇二〇年十月 1 联化科技股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王萍、主管会计工作负责人陈飞彪及会计机构负责人(会计主管 人员)许明辉声明：保证季度报告中财务报表的真实、准确、完整。 2 联化科技股份有限公司 2020 年第三季度报告全文 非经常性损益项目和金额 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | --- | --- | --- | --- | --- | |-----------------------------------------------------|----------------------------------------------------------------|------ ...

联化科技股份有限公司 2020 年半年度报告全文 联化科技股份有限公司 2020 年半年度报告 二〇二〇年八月 1 联化科技股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人王萍、主管会计工作负责人陈飞彪及会计机构负责人(会计主管 人员)许明辉声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展计划等前瞻性陈述属于计划性事项，不构成公司 对投资者的实质性承诺，敬请投资者注意投资风险。 | --- | --- | |--------------------------------------------------------|----------------------------------------| | | | | 有关风险因素内容与对策措施已在本报告 " 第四节 | 经营情况讨论与分析 " | | 中 " 十、公司面临的风险和应对措施 " | 予以描 ...

联化科技股份有限公司 2020 年第一季度报告全文 联化科技股份有限公司 2020 年第一季度报告 二〇二〇年四月 1 联化科技股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王萍、主管会计工作负责人陈飞彪及会计机构负责人(会计主管 人员)许明辉声明：保证季度报告中财务报表的真实、准确、完整。 2 联化科技股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|-------|------------------|--------------------------| | □ 是 √ 否 | 本报告期 ...

联化科技股份有限公司 2019 年年度报告全文 联化科技股份有限公司 2019 年度报告 二〇二〇年四月 1 联化科技股份有限公司 2019 年年度报告全文 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带 的法律责任。 公司负责人王萍、主管会计工作负责人陈飞彪及会计机构负责人(会计主管 人员)许明辉声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展计划等前瞻性陈述属于计划性事项，不构成公司 对投资者的实质性承诺，敬请投资者注意投资风险。 本公司请投资者认真阅读本年度报告全文，并特别注意本报告第四节"经营 情况讨论与分析"中"九、公司未来发展的展望"部分的阐述。 公司经本次董事会审议通过的利润分配预案为：以未来实施分配方案时股 权登记日的公司总股本为基数，向全体股东每10股派发现金红利0.5元（含税）， 送红股 0 股（含税），不以公积金转增股本。 2 联化科技股份有限公司 2019 年年度报告全文 目录 | --- | |--- ...

联化科技股份有限公司 2019 年第三季度报告全文 联化科技股份有限公司 2019 年第三季度报告 二○一九年十月 1 联化科技股份有限公司 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王萍、主管会计工作负责人陈飞彪及会计机构负责人(会计主管 人员)许明辉声明：保证季度报告中财务报表的真实、准确、完整。 2 联化科技股份有限公司 2019 年第三季度报告全文 会计政策变更 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------------------------------------|----------------|------------------------- ...

联化科技股份有限公司 2019 年半年度报告全文 联化科技股份有限公司 2019 年半年度报告 二〇一九年八月 1 联化科技股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人王萍、主管会计工作负责人陈飞彪及会计机构负责人(会计主管 人员)许明辉声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展计划等前瞻性陈述属于计划性事项，不构成公司 对投资者的实质性承诺，敬请投资者注意投资风险。 | --- | --- | |--------------------------------------------------------|----------------------------------------| | | | | 有关风险因素内容与对策措施已在本报告 " 第四节 | 经营情况讨论与分析 " | | 中 " 十、公司面临的风险和应对措施 " | 予以描 ...

联化科技股份有限公司 2019 年第一季度报告全文 联化科技股份有限公司 2019 年第一季度报告 二〇一九年四月 1 联化科技股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人王萍、主管会计工作负责人陈飞彪及会计机构负责人(会计主管 人员)许明辉声明：保证季度报告中财务报表的真实、准确、完整。 2 联化科技股份有限公司 2019 年第一季度报告全文 会计政策变更的原因及会计差错更正的情况 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 √ 是 □ 否 追溯调整或重述原因 会计政策变更 | --- | --- | --- | --- | --- | |-----------------------------------------------------|------------------|-------------------|------- ...

联化科技股份有限公司 2018 年度报告全文 联化科技股份有限公司 2018 年度报告 二〇一九年四月 1 联化科技股份有限公司 2018 年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人王萍、主管会计工作负责人陈飞彪及会计机构负责人(会计主管 人员)许明辉声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中涉及的未来发展计划等前瞻性陈述属于计划性事项，不构成公司 对投资者的实质性承诺，敬请投资者注意投资风险。 本公司请投资者认真阅读本年度报告全文，并特别注意本报告第四节"经营 情况讨论与分析"中"九、公司未来发展的展望"部分的阐述。 公司经本次董事会审议通过的利润分配预案为：以未来实施分配方案时股 权登记日的公司总股本为基数，向全体股东每10股派发现金红利0.20元（含税）， 送红股 0 股（含税），不以公积金转增股本。 2 联化科技股份有限公司 2018 年度报告全文 目录 | --- | |---- ...

Financial Performance - Operating revenue for the current period was ¥786,649,414.36, down 18.80% year-on-year[7] - Net profit attributable to shareholders was a loss of ¥22,112,720.82, a decrease of 1,103.62% compared to the same period last year[7] - Basic earnings per share were -¥0.0239, a decline of 1,019.23% year-on-year[7] - Operating revenue for the year-to-date was ¥2,606,352,892.78, a decrease of 10.31% compared to the same period last year[16] - Net cash flow from operating activities dropped by 69.79% to ¥156,748,754.89, mainly due to reduced cash receipts from sales[16] - The company experienced a 52.90% decrease in income tax expenses to ¥21,958,866.87, due to a reduction in total profit[16] - The net profit attributable to shareholders for 2018 is expected to range from ¥20,134.12 million to ¥12,080.47 million, reflecting a decrease of 40% to 90% compared to the previous year[20] Assets and Liabilities - Total assets decreased by 9.90% to ¥7,796,258,978.23 compared to the end of the previous year[7] - Cash and cash equivalents decreased by 50.32% to ¥569,946,731.64 due to no fundraising activities in the current period[15] - Accounts receivable decreased by 46.07% to ¥37,556,656.68, primarily due to reduced sales settled through notes[15] - Other non-current assets decreased by 92.98% to ¥36,068,516.33, primarily due to the recovery of collateral for loans to a UK subsidiary[15] - The company’s derivative financial liabilities rose by 1023.39% to ¥5,977,388.85, resulting from unrealized losses on hedging instruments[15] - The fair value of financial derivatives increased to ¥5,445,302.10, with a total ending amount of ¥5,977,388.85[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,429[11] - The largest shareholder, Mu Jinxiang, holds 27.49% of the shares, totaling 254,535,853 shares[11] - The company reported no significant changes in its shareholder structure or any repurchase transactions during the reporting period[12] Non-Operating Income and Expenses - Non-operating income included government subsidies amounting to ¥8,486,672.23[8] - Financial expenses increased by 34.92% to -¥27,755,058.28, mainly due to increased foreign exchange gains[16] - The company reported a significant increase in other income by 344.24% to ¥18,638,946.14, primarily from relocation compensation received[16] Operational Challenges and Future Outlook - The main subsidiaries, Jiangsu Lianhua and Yancheng Lianhua, experienced a shutdown for nearly 3.5 months starting from the end of April 2018, impacting profits in Q2 and Q3[20] - The company anticipates a recovery in performance in Q4 2018, returning to normal levels[20] Governance and Compliance - There were no violations regarding external guarantees during the reporting period[23] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[24] - The company did not engage in entrusted financial management during the reporting period[25] - No research, communication, or interview activities were conducted during the reporting period[26] Compensation and Performance Measures - The company remains committed to fulfilling its promises regarding stock incentives and performance measures[19] - The company’s compensation system is linked to the execution of performance recovery measures[19]

Financial Performance - The company's operating revenue for the reporting period was ¥1,819,703,478.42, a decrease of 6.07% compared to the same period last year [19]. - The net profit attributable to shareholders was ¥9,145,422.83, representing a significant decline of 94.57% year-over-year [19]. - The net profit after deducting non-recurring gains and losses was ¥68,111,773.36, down 60.13% from the previous year [19]. - The net cash flow from operating activities was ¥96,227,096.14, a decrease of 62.07% compared to the same period last year [19]. - The total assets at the end of the reporting period were ¥7,777,803,834.79, reflecting a decline of 10.11% from the end of the previous year [19]. - The company's gross profit margin for the industrial sector was 34.71%, a decrease of 2.38% year-on-year [62]. - The company's liquidity ratios showed a significant decline, with the current ratio decreasing by 102.78% to 136.67% and the quick ratio decreasing by 78.14% to 76.11% compared to the end of the previous year [172]. - The EBITDA interest coverage ratio fell by 43.84% to 7.2, primarily due to production halts for environmental inspections, resulting in an 83.95% decrease in earnings before interest, taxes, depreciation, and amortization (EBITDA) [172]. - The company reported a total comprehensive income of CNY -8,904,268.54 for the first half of 2018, contrasting sharply with CNY 176,787,119.23 in the same period last year [192]. - Basic earnings per share fell to CNY 0.01 from CNY 0.20, reflecting the decline in net profit [192]. Investment and Cash Flow - The total cash inflow from investment activities was ¥452,480,177.86, significantly higher than ¥25,344,579.10 in the previous period [200]. - The net cash flow from financing activities was -¥700,031,846.58, contrasting with a positive cash flow of ¥1,245,999,828.80 in the previous period [200]. - The total cash and cash equivalents at the end of the period amounted to ¥653,899,144.08, down from ¥1,377,868,224.63 at the beginning of the period [200]. - Cash outflow for operating activities totaled ¥1,907,239,482.11, compared to ¥1,547,094,604.35 in the previous period, indicating increased operational expenses [199]. - The company received tax refunds totaling ¥95,046,248.72, compared to ¥27,924,808.67 in the previous period, showing improved tax recovery [199]. Business Operations and Strategy - The company operates in the fine chemical industry, focusing on the production of intermediates and active pharmaceutical ingredients [11]. - The company is involved in contract development and manufacturing, providing services for the production of pharmaceuticals and intermediates [11]. - The company has established strategic partnerships with several international pharmaceutical giants, enhancing its competitive position in the pharmaceutical sector [29]. - The company aims to enhance its value chain through integration, self-development, and mergers in the functional chemicals sector [30]. - The company has maintained a significant market position in the pesticide sector, with the top five companies controlling approximately 70% of the market [28]. - The company has developed a customized production model, collaborating with core clients on project development to enhance its market responsiveness [46]. Research and Development - Research and development investment increased by 22.66% year-on-year, totaling 98,256,996.72 yuan [58]. - As of June 2018, the company holds 51 domestic invention patents and has 34 invention patents pending, showcasing its commitment to innovation [41]. - The company has been recognized as a key high-tech enterprise under the National Torch Program and has received global supplier technology innovation awards in the pesticide industry [40]. Environmental Management - The report discusses the company's commitment to safety, health, and environmental management systems [10]. - The company has established wastewater treatment facilities with capacities of 1000t/d, 3500t/d, 2500t/d, 4000t/d, 1000t/d, and 500t/d across its subsidiaries [135]. - The total COD emissions from the company were 12.716 tons, with a concentration of 213.43 mg/L, well below the limit of 500 mg/L [131]. - The company has implemented RTO tail gas incineration systems and solid waste incineration facilities to manage emissions effectively [135]. - The company has established comprehensive pollution control measures, including noise control and waste management, to minimize environmental impact [135]. Risks and Challenges - The company faces significant risks from macroeconomic fluctuations, particularly as its overseas business revenue is substantial, with potential impacts from economic slowdowns in North America and Europe [89]. - Environmental protection regulations are becoming stricter, which may increase the company's expenditures on pollution control and could lead to penalties if compliance is not met [90]. - Currency exchange rate fluctuations pose a risk to the company's export-oriented business, and measures are in place to mitigate this through contractual agreements and financial derivatives [92]. - New product development carries risks, particularly in the pharmaceutical sector where some products are still in clinical research, potentially affecting market launch and expectations [94]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 26,206 [152]. - The largest shareholder, Mu Jinxiang, holds 27.49% of the shares, totaling 254,535,853 shares, which are pledged [152]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [154]. - The top ten shareholders do not have any related party relationships or concerted actions among them [153]. Corporate Governance - The board of directors has confirmed that all members attended the meeting to review the report [5]. - The company has not engaged in any related party transactions during the reporting period [116]. - There were no asset or equity acquisitions or sales during the reporting period [117]. - The company has approved external guarantees totaling CNY 5,000,000, with an actual guarantee amount of CNY 2,000,000 during the reporting period [125].